olokizumab
Jump to navigation
Jump to search
Indications
- long-term managemtne of rheumatoid arthritis in combination with methotrexate
Dosage
- subcutaneous once every 2 weeks or once every 4 weeks
Adverse effects
Mechanism of action
- humanized monoclonal antibody targeting interleukin-6
More general terms
References
- ↑ Feist E, Fleischmann RM, Fatenejad S et al Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024 Jul 2:ard-2023-225473. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38955475 Free article.
- ↑ Smolen JS, Feist E, Fatenejad S Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36001712 Clinical Trial. https://www.nejm.org/doi/10.1056/NEJMoa2201302